1984
BCVPP chemotherapy for advanced Hodgkin's disease: evidence for greater duration of complete remission, greater survival, and less toxicity than with a MOPP regimen. Results of the Eastern Cooperative Oncology Group study.
Bakemeier R, Anderson J, Costello W, Rosner G, Horton J, Glick J, Hines J, Berard C, DeVita V. BCVPP chemotherapy for advanced Hodgkin's disease: evidence for greater duration of complete remission, greater survival, and less toxicity than with a MOPP regimen. Results of the Eastern Cooperative Oncology Group study. Annals Of Internal Medicine 1984, 101: 447-56. PMID: 6089632, DOI: 10.7326/0003-4819-101-4-447.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntineoplastic Combined Chemotherapy ProtocolsBlood Cell CountCarmustineClinical Trials as TopicCombined Modality TherapyCyclophosphamideFemaleGastrointestinal DiseasesHematologic DiseasesHodgkin DiseaseHumansMaleMechlorethamineNeoplasm StagingPeripheral Nervous System DiseasesPrednisoneProcarbazineRandom AllocationVinblastineVincristineConceptsAdvanced Hodgkin's diseaseHodgkin's diseaseUntreated patientsEastern Cooperative Oncology Group studyDuration of complete remissionRandomized prospective studyTreatment of patientsMOPP regimenHematologic toxicityInduction chemotherapyComplete remissionChemotherapy regimensRemission rateNeurological toxicityProspective studyMOPPRemissionTherapeutic benefitChemotherapyPatientsInduction phaseDiseaseToxicityGroup studyDuration
1974
Clinical antitumor activity and toxicity of streptozotocin (NSC‐85998)
Schein P, O'Connell M, Blom J, Hubbard S, Magrath I, Bergevin P, Wiernik P, Ziegler J, Devita V. Clinical antitumor activity and toxicity of streptozotocin (NSC‐85998). Cancer 1974, 34: 993-1000. PMID: 4371075, DOI: 10.1002/1097-0142(197410)34:4<993::aid-cncr2820340404>3.0.co;2-t.Peer-Reviewed Original ResearchConceptsMalignant carcinoid tumorsNormal renal functionIslet cell carcinomaClinical antitumor activityAcute lymphocytic leukemiaToxicity of streptozotocinHematologic toxicityAdvanced malignanciesRenal damageRenal functionCarcinoid tumorsHodgkin's diseaseCell carcinomaLymphocytic lymphomaTherapeutic responseLymphocytic leukemiaTumor massBurkitt's lymphomaDrug effectsMaximum dosesPatientsTotal doseStreptozotocinLymphomaAntitumor activity
1973
Combined drug treatment of Hodgkin's disease: remission induction, remission duration, and survival; an appraisal.
DeVita V. Combined drug treatment of Hodgkin's disease: remission induction, remission duration, and survival; an appraisal. National Cancer Institute Monograph 1973, 36: 373-9. PMID: 4744596.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsAntineoplastic AgentsBiopsyCarmustineChlorambucilCyclophosphamideDactinomycinDrug Therapy, CombinationEvaluation Studies as TopicFollow-Up StudiesHodgkin DiseaseHumansMechlorethamineMiddle AgedPrednisoneProcarbazineRemission, SpontaneousTime FactorsVinblastineVincristineCurrent chemotherapeutic combinations.
DeVita V, Carbone P. Current chemotherapeutic combinations. Series Haematologica (1968) 1973, 6: 182-95. PMID: 4593779.Peer-Reviewed Original Research
1967
The physiological disposition of the carcinostatic 1,3‐bis(2‐chloroethyU‐l‐nitrosourea (BCNU) in man and animals
DeVita V, Denham C, Davidson J, Oliverio V. The physiological disposition of the carcinostatic 1,3‐bis(2‐chloroethyU‐l‐nitrosourea (BCNU) in man and animals. Clinical Pharmacology & Therapeutics 1967, 8: 566-577. PMID: 4951973, DOI: 10.1002/cpt196784566.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsCarmustineDogsFemaleHumansMacaca mulattaMaleMiceMice, Inbred StrainsSpecies Specificity
1966
Pigmentation due to a new antitumor agent. Effects of topical application of BCNU [1,3-bis(2-chloroethyl)-1-nitrosourea].
Frost P, DeVita V. Pigmentation due to a new antitumor agent. Effects of topical application of BCNU [1,3-bis(2-chloroethyl)-1-nitrosourea]. JAMA Dermatology 1966, 94: 265-8. PMID: 4951807, DOI: 10.1001/archderm.94.3.265.Peer-Reviewed Original Research